ALNYLAM PHARMACEUTICALS, INC. reports

Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Cambridge, MA
SEC filing record 1 source field available
Fiscal year end
31 December
ALNYLAM PHARMACEUTICALS, INC. has filed 1,677 SEC EDGAR filings since 09 Jul 2002

SEC filing history

Showing 801-825 of 1,000 matching filings.

Per page
25
Current page
33
SC 13G File 005-79884

SC 13G filing

Filing date
30 Jan 2017
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
4

PRIMARY DOCUMENT

Filing date
27 Jan 2017
Reporting date
25 Jan 2017
SEC evidence
Open document Open filing
Next action
Verify source filing
4

PRIMARY DOCUMENT

Filing date
20 Jan 2017
Reporting date
18 Jan 2017
SEC evidence
Open document Open filing
Next action
Verify source filing
4

PRIMARY DOCUMENT

Filing date
06 Jan 2017
Reporting date
05 Jan 2017
SEC evidence
Open document Open filing
Next action
Verify source filing
4

PRIMARY DOCUMENT

Filing date
04 Jan 2017
Reporting date
30 Dec 2016
SEC evidence
Open document Open filing
Next action
Verify source filing
4

PRIMARY DOCUMENT

Filing date
03 Jan 2017
Reporting date
30 Dec 2016
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-36407

8-K

Filing date
03 Jan 2017
Reporting date
29 Dec 2016
SEC evidence
Open document Open filing
Next action
Verify source filing
4

PRIMARY DOCUMENT

Filing date
22 Dec 2016
Reporting date
20 Dec 2016
SEC evidence
Open document Open filing
Next action
Verify source filing
4

PRIMARY DOCUMENT

Filing date
22 Dec 2016
Reporting date
20 Dec 2016
SEC evidence
Open document Open filing
Next action
Verify source filing
4

PRIMARY DOCUMENT

Filing date
22 Dec 2016
Reporting date
20 Dec 2016
SEC evidence
Open document Open filing
Next action
Verify source filing
4

PRIMARY DOCUMENT

Filing date
22 Dec 2016
Reporting date
20 Dec 2016
SEC evidence
Open document Open filing
Next action
Verify source filing
4

PRIMARY DOCUMENT

Filing date
22 Dec 2016
Reporting date
20 Dec 2016
SEC evidence
Open document Open filing
Next action
Verify source filing
4

PRIMARY DOCUMENT

Filing date
22 Dec 2016
Reporting date
20 Dec 2016
SEC evidence
Open document Open filing
Next action
Verify source filing
4

PRIMARY DOCUMENT

Filing date
22 Dec 2016
Reporting date
20 Dec 2016
SEC evidence
Open document Open filing
Next action
Verify source filing
4

PRIMARY DOCUMENT

Filing date
14 Dec 2016
Reporting date
12 Dec 2016
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G File 005-79884

SCHEDULE 13G

Filing date
09 Dec 2016
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-79884

SC 13G/A filing

Filing date
09 Dec 2016
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
4

PRIMARY DOCUMENT

Filing date
05 Dec 2016
Reporting date
01 Dec 2016
SEC evidence
Open document Open filing
Next action
Verify source filing
4

PRIMARY DOCUMENT

Filing date
02 Dec 2016
Reporting date
30 Nov 2016
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-36407

ALNYLAM PHARMACEUTICALS, INC. 8-K

Filing date
02 Nov 2016
Reporting date
02 Nov 2016
SEC evidence
Open document Open filing
Next action
Verify source filing
4

PRIMARY DOCUMENT

Filing date
14 Oct 2016
Reporting date
13 Oct 2016
SEC evidence
Open document Open filing
Next action
Verify source filing
4

PRIMARY DOCUMENT

Filing date
14 Oct 2016
Reporting date
12 Oct 2016
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-36407

8-K

Filing date
05 Oct 2016
Reporting date
05 Oct 2016
SEC evidence
Open document Open filing
Next action
Verify source filing
4

PRIMARY DOCUMENT

Filing date
21 Sep 2016
Reporting date
19 Sep 2016
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .